|View printer-friendly version|
Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer
July 24, 2017 at 8:00 AM EDT
SGN-LIV1A to be Investigated in Combination with Atezolizumab as Part of Initiative for the Development of Novel Cancer Immunotherapy Combinations
“A key challenge in triple-negative breast cancer, or TNBC, is the lack
of available novel targeted treatments. People with this disease
generally have poor prognoses. Moreover, current therapies are not
curative and only delay disease progression,” said
SGN-LIV1A administered in combination with atezolizumab will be
evaluated in a phase 1b/2 clinical study as second-line therapy in
patients with metastatic TNBC who have not been previously treated with
immunotherapy. This randomized, controlled study is anticipated to
enroll up to 45 patients in the treatment arm.
Under the terms of the collaboration agreement, Genentech will manage
the study operations for the phase 1b/2 trial.
SGN-LIV1A is a novel investigational ADC targeted to LIV-1 protein utilizing Seattle Genetics’ proprietary ADC technology. LIV-1 is expressed by most metastatic breast cancers. It has also been detected in a number of other cancers, including melanoma, prostate, ovarian, and cervical cancer. SGN-LIV1A consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker, using the same technology as ADCETRIS (brentuximab vedotin). It is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. SGN-LIV1A may also cause antitumor activity through other mechanisms, including activation of an immune response.
TECENTRIQ® (atezolizumab) is a registered trademark of
Genentech, a member of the
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the therapeutic
potential of SGN-LIV1A and its possible benefits and uses, as
monotherapy or in combination with atezolizumab. Actual results or
developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include the inability of SGN-LIV1A to show sufficient
activity in the clinical setting referenced above and the risk of
adverse events of SGN-LIV1A alone or in combination with atezolizumab.
More information about the risks and uncertainties faced by